Navigation Links
NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase®*)
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona.  The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling."

DAS181 (Fludase®) is an investigational broad spectrum host-targeting antiviral drug candidate undergoing clinical development for the treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza (PIV).  These new data show that, independent of its antiviral activity, and by a different mechanism of action, DAS181 may have benefit for airway diseases such as asthma and COPD.

NexBio presented nonclinical data at ACAAI 2009 from studies in three animal models of asthma, demonstrating that DAS181 inhibits airway hyperreactivity characteristic of asthma, as well as airway inflammatory cells and airway mucus, characteristic of chronic airway inflammatory conditions such as COPD.  The current presentation at 2010 ACAAI builds on this prior work by elucidating a key mechanism of action.  The data demonstrate that desialylation of airway muscarinic receptors in both in vivo and in vitro models unexpectedly reduces muscarinic pathway signaling. DAS181 given to mice once daily for three days, at doses lower than those used for antiviral treatment, leads to significantly reduced airway resistance in response to challenge by methacholine.

"The data suggest that DAS181 may have a dual benefit for patients with airway disease who become infected with the respiratory viruses influenza and parainfluenza, as DAS181 may fight infection while simultaneously controlling the underlying airway disease.  These patients are at high risk for exacerbations of their airway disease, as was seen during the 2009 Pandemic, and it is possible that DAS181 may limit or prevent complications," said Dr. Ron Moss, NexBio's Executive Vice President of Clinical Development and Medical Affairs, and presenter of the data.  "These new data also suggest that DAS181 might be useful as a novel, once-daily anti-muscarinic agent for the management of patients with diseases such as asthma and COPD, and an ongoing clinical trial is assessing this possibility," added Dr. Moss.  

DAS181 is an investigational drug currently in an ongoing Phase 2 clinical trial of subjects infected with influenza. NexBio has previously announced the publication of several articles in peer-reviewed journals describing non-clinical activity of DAS181 for Pandemic Influenza A(H1N1), neuraminidase inhibitor (NAI)-resistant influenza, avian H5N1, and, PIV strains, in ex vivo, in vivo and in vitro models. As well, a Phase 1/2 study of the safety and activity of DAS181 for (uninfected) patients with asthma and bronchiectasis is ongoing at the Clinical Center at the National Institutes of Health.  

ABOUT NEXBIO

NexBio, Inc. is a privately held clinical-stage biopharmaceutical company located in San Diego.  NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases.  DAS181 (Fludase®) is an investigational drug in Phase 2 that consists of an inhaled recombinant fusion protein.  It inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic).  The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under BAA Contract HHSN266200600015C and grant U01-AI070281. SepcidinTM, invented and developed by NexBio, is a parenteral protein at pre-clinical lead optimization stage, directed to the treatment of sepsis/SIRS, viral hemorrhagic fevers, bacterial biothreat agents.  TOSAP®, a technology invented and developed by NexBio, is used to formulate DAS181 for inhalation, as well as to make microparticles from virtually any type of large and small molecule, and combinations of molecules. TOSAP is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.comContact:David Wurtman, M.D., M.B.A.VP, Corporate Development5 Sorrento Valley RoadSan Diego, CA  92121Phone: (858) 452-2631dwurtman@nexbio.com* FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.
'/>"/>

SOURCE NexBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
2. NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
3. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
4. AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
5. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
8. Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine
9. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
10. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
11. Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):